Sun Pharmaceutical Industries Ltd. has reported a 27% year-on-year increase in consolidated net profit for the quarter ended June 30, 2026, supported by strong revenue growth and improved operational performance. The company’s net profit attributable to owners rose to ₹2,894.79 crore, compared with ₹2,278.63 crore in the same quarter last year.
The company’s consolidated revenue from operations increased by 10.5% to ₹15,299.88 crore from ₹13,851.40 crore in the previous year. Sales excluding other operating revenue also grew by 10.1% to ₹15,183.55 crore.
However, the company witnessed pressure on operating margins during the quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 2.7% to ₹4,417.70 crore, while the EBITDA margin declined to 28.9% from 31.1% a year earlier due to higher expenses.
Sun Pharma’s India formulations business recorded strong growth, with sales rising 16% to ₹5,474.89 crore, driven by key segments including cardiovascular, central nervous system, gastroenterology and orthopaedic portfolios. Global innovative medicines sales also increased by 12.9% to $351 million.
Meanwhile, US formulations sales declined 9.7% during the quarter, impacted by challenges in the generics segment, including lenalidomide. Sales in emerging markets and active pharmaceutical ingredients also showed positive growth.
The company’s earnings per share increased to ₹12.10 from ₹9.50, reflecting improved profitability. Sun Pharma continues to focus on expanding its innovative medicines portfolio while strengthening its presence across global markets.
